What RxC International does

RxC International is a privately held, US-based life sciences management consulting firm founded in 2013 and headquartered in Morristown, New Jersey, with additional offices in Cambridge, Massachusetts and San Diego, California. The firm focuses exclusively on biopharma strategy, serving large-cap pharmaceutical companies (including Fortune 100 names such as Merck, Novartis, Sanofi, AstraZeneca, and AbbVie) as well as mid-cap and specialty biotech clients across the US, EU5, Japan, and other key markets. Its work spans corporate strategy, new product planning, commercialization strategy, life cycle management, and licensing/M&A advisory.

The firm's core deliverables are organized around three proprietary consulting solutions: ProPlan™ for new product planning and R&D-stage assessment, ProLOGS™ for product lifecycle optimization, and ProComS™ for commercialization strategy. These methodologies are complemented by three published reference books on biopharma commercialization, value chain management, and investing, plus ongoing white papers and resource centers covering gene therapy, biosimilars, co-promotion, and rare diseases. A formal Executive Advisor board of former senior pharma leaders (from Sanofi, Daiichi Sankyo, GSK, NIH, OPKO, and others) supports client engagements and credibility.

RxC generates revenue through project-based professional consulting engagements pursued via direct enterprise field sales to biopharma corporate development, brand, and cross-functional leadership teams. The firm employs a thought leadership-driven go-to-market motion, publishing in Pharmaceutical Executive and similar outlets, and reports delivery of more than 100 strategic engagements to over 30 global biopharma companies since inception. Specific pricing, fee structures, and revenue figures are not publicly disclosed.

Name

RxC International

Legal name

RxC International Inc.

Website

https://rxcinternational.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

RxC International is a privately held US life sciences management consulting firm that delivers biopharma strategy services — new product planning, lifecycle optimization, and commercialization — to large-cap and mid-cap pharma and biotech clients via three proprietary frameworks (ProPlan, ProLOGS, ProComS).

Ownership category

akta.pro rank

Headquarters

HQ city

Morristown

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Strategic Consulting Engagements: RxC International generates revenue through professional consulting engagements with biopharma companies. Engagements cover corporate strategy, new product planning, and commercialization strategy across therapeutic areas. Revenue is derived from project-based consulting fees, likely structured as retainers or milestone-based payments typical of management consulting engagements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

RxC International is a premier life sciences management consulting firm that delivers strategic consulting engagements to biopharma companies through three proprietary solutions: ProPlan™ (new product planning), ProLOGS™ (product lifecycle optimization and growth strategy), and ProComS™ (new product commercialization strategy). Engagements cover corporate strategy, new product planning, life cycle management, and commercialization for pharmaceutical and biotechnology clients across the US, EU5, Japan, and other key markets.

Product overview

RxC International is a premier biopharma strategy consulting firm that offers a portfolio of proprietary consulting solutions alongside published knowledge resources. The core offerings consist of three proprietary frameworks: ProPlan™ for new product planning and assessment, ProLOGS™ for product lifecycle optimization and growth strategy, and ProComS™ for new product commercialization strategy. These three solutions work together to cover the full product lifecycle from early-stage R&D evaluation through commercialization and lifecycle management. Additionally, the firm publishes white papers, maintains resource centers on specialized topics (Gene Therapy, Biosimilars, Co-Promotion), and has authored practical reference guides on biopharma commercialization and investment.

Differentiator

Problem solved

Functional benefit

Brands

• ProPlan™: Proprietary solution for comprehensive evaluation of medical, scientific, clinical, regulatory, tech ops, and commercialization issues around new products in research & development
• ProLOGS™
• ProComS™
• RxC Corporate Research

Products and services

• ProPlan™ (New Product Planning) Proprietary new product planning solution providing comprehensive evaluation of medical, scientific, clinical, regulatory, tech ops, and commercialization issues around new products in research & development; guides biopharma companies through new product investment decisions.
• ProLOGS™ (Product Lifecycle Optimization and Growth Strategy) Proprietary product lifecycle optimization and growth strategy solution designed to uncover new life cycle opportunities for products in early, mid, and late stages and translate them into value-creating opportunities for biopharma clients.
• ProComS™ (New Product Commercialization Strategy) Proprietary new product commercialization strategy solution helping clients navigate through every step of the commercialization process, leveraging best practices from successful product launches in therapeutic areas.

Quantifiable outcome

• Delivered outcomes to more than 30 global biopharma companies in US, EU5, Japan, and other key markets
• +1 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Trinity Partners: Boutique consulting firm focused on biopharma strategy, with services spanning new product planning, commercial assessment, and market access. Comparable in size and scope to RxC; now operating as part of Ipsos Healthcare.
• ClearView Healthcare Partners: Boutique biopharma strategy consulting firm focused on commercialization, new product planning, and corporate strategy. Directly comparable to RxC in size, focus, and Fortune 500 biopharma client base.
• Simon-Kucher & Partners: Global consulting firm with leading life sciences practice focused on pricing, market access, and commercial strategy. Comparable to RxC on commercialization strategy and growth-oriented engagements for pharma/biotech, with a particular overlap in lifecycle pricing and access work.
• Health Advances: Boutique strategy consulting firm focused exclusively on biopharma, medtech, and diagnostics. Highly comparable to RxC in targeting commercial strategy, market access, and new product planning for biopharma clients at small/mid-cap through large-cap.
• Putnam Associates: Boutique biopharma strategy consulting firm founded by former Bain consultants. Closely comparable to RxC in size, focus (commercial strategy, new product planning, lifecycle management), and client base across pharma and biotech. RxC Strategy Partner Rich Tinsley is a former Putnam principal.
• L.E.K. Consulting: Global strategy consulting firm with a dedicated Life Sciences practice spanning pharma, biotech, and medtech. Directly comparable to RxC on commercial strategy, new product planning, and M&A advisory for biopharma clients.
• ZS Associates: Large global consulting firm with a flagship healthcare/biopharma practice covering commercial strategy, launch, sales, and market access. Comparable to RxC in serving enterprise biopharma on commercialization decisions, though at significantly greater scale and with a heavier data/technology orientation.

Broad incumbents

• Charles River Associates: Global consulting firm with a Life Sciences practice offering commercial strategy, market access, and litigation support to biopharma. Overlaps with RxC on commercialization and lifecycle work but operates across multiple industries and with a broader service portfolio.
• Bain & Company: Global Tier 1 strategy firm with a major Healthcare and Life Sciences practice. Directly competes with RxC for biopharma strategy engagements at the high end of the market, and is the prior employer of RxC Strategy Partner Rich Tinsley.
• McKinsey & Company: Global Tier 1 strategy firm with a dedicated Pharma & Medical Products practice. Competes for the largest biopharma strategy mandates; sets the pricing benchmark and senior-talent compensation ceiling that influences RxC's positioning and cost structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rxc-international

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RxC International